AMRX vs TEVA vs VTRS vs PRGO vs PAHC

For growth investors, Phibro Animal Health Corporation (PAHC) is the stronger pick with 27.

4% revenue growth year-over-year, versus -3. 0% for Viatris Inc. (VTRS). Teva Pharmaceutical Industries Limited (TEVA) offers the better valuation at 30. 0x trailing P/E (14. 5x forward), making it the more compelling value choice. Analysts rate Amneal Pharmaceuticals, Inc. (AMRX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Teva Pharmaceutical Industries Limited (TEVA) is the cheapest at 30.

0x versus Amneal Pharmaceuticals, Inc. at 62. 4x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Teva Pharmaceutical Industries Limited (TEVA) delivered a total return of +246.

2%, compared to -60. 1% for Perrigo Company plc (PRGO). Over 10 years, the gap is even starker: PAHC returned +128. 6% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Viatris Inc.

(VTRS) is the lower-risk stock at 0. 99β versus Phibro Animal Health Corporation's 1. 38β — meaning PAHC is approximately 39% more volatile than VTRS relative to the S&P 500. On balance sheet safety, Amneal Pharmaceuticals, Inc. (AMRX) carries a lower debt/equity ratio of 13% versus 3% for Phibro Animal Health Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Phibro Animal Health Corporation (PAHC) is pulling ahead at 27.

4% versus -3. 0% for Viatris Inc. (VTRS). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, PAHC leads at 11. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Teva Pharmaceutical Industries Limited (TEVA) is the more profitable company, earning 8.

2% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 8. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TEVA leads at 12. 5% versus -18. 6% for VTRS. At the gross margin level — before operating expenses — TEVA leads at 51. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

6x forward P/E versus 14. 5x for Teva Pharmaceutical Industries Limited — 9. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.

In this comparison, PRGO (9.

8% yield), VTRS (2. 8% yield), PAHC (1. 1% yield) pay a dividend. AMRX, TEVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Viatris Inc.

(VTRS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 99), 2. 8% yield). Both have compounded well over 10 years (VTRS: -51. 5%, AMRX: -54. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AMRX is a small-cap quality compounder stock; TEVA is a mid-cap quality compounder stock; VTRS is a mid-cap quality compounder stock; PRGO is a small-cap income-oriented stock; PAHC is a small-cap high-growth stock. VTRS, PRGO, PAHC pay a dividend while AMRX, TEVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.